Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 29, 2020

View Archived Issues

Sudoku-solving algorithm predicts protein structure, too

Statins help pancreatic tumors go from bad to worse

Livin targeting: a promising immunotherapy for lymphomas resistant to Fas-mediated apoptosis

Annexon studies ANX-005 for Huntington's disease in phase II

Medicines for Malaria Venture begins phase I study of MMV-688533

FSD Pharma initiates phase II study of FSD-201 in hospitalized patients with COVID-19

ORIENT-32 study meets primary endpoints at interim analysis

Achelois Oncology describes CAR T cells expressing CD160

Cue Biopharma presents T-cell modulatory antigen-presenting polypeptides

New anti-CD47 antibodies disclosed by Beijing Guangwei Biotechnology

Quantum Genomics and collaborators present glutamyl aminopeptidase inhibitors

New sphingosine 1-phosphate receptor 1 ligands discovered at the University of Buea

Cerebral palsy risk has genetic component

FDA approves Fetroja for the treatment of HABP and VABP

FDA grants IND approval for phase II/III study of CardiolRx in patients with COVID-19

Ultomiris approved in Japan for aHUS in adults and children

Tecentriq and Avastin approved in Japan as first cancer immunotherapy for unresectable HCC

Phase I results reported for fusion protein tTF-NGR in advanced cancer patients

Enaroy approved in Japan for anemia associated with chronic kidney disease

First clinical data for AMG-160, a bispecific T-cell engager immunotherapeutic

Daewoong reports phase II data on enavogliflozin for type 2 diabetes

European Commission approves Heron's Zynrelef for postoperative pain

Sobrera and Recipharm collaborate on formulation development of SO-001 for alcohol use disorder

Primary endpoint not met with ipatasertib added to paclitaxel in HR+, HER2- breast cancer

Sarepta reports 2-year data with SRP-9001 gene therapy for DMD

FDA places partial clinical hold on planned phase II/III trial of INO-4800

Aligos receives CTA clearance to begin first-in-human study of ALG-000184 for hepatitis B

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...